Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, and selective phosphodiesterase 9 (PDE9) inhibitor to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease.
|HQ||Boston, MA, US||Map|
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (21-Oct-2021)
Closing stock price (21-Oct-2021)
Imara has 253 Twitter Followers. The number of followers has increased 0.6% month over month and increased 1.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Imara founded?
Imara was founded in 2015.
Who are Imara key executives?
Imara's key executives are Rahul D. Ballal, Rahul Ballal and Kenneth Attie.
How many employees does Imara have?
Imara has 20 employees.
Who are Imara competitors?
Competitors of Imara include Cassava Sciences, Strand Therapeutics and ReViral.
Where is Imara headquarters?
Imara headquarters is located at 116 Huntington Ave 6th floor, Boston.
Where are Imara offices?
Imara has an office in Boston.
How many offices does Imara have?
Imara has 1 office.
Receive alerts for 300+ data fields across thousands of companies